ABOUT US
About Us
Pioneers of Advanced Diagnostics and Specialized Gene Editing
About Us
Pioneers of Advanced Diagnostics and Specialized Gene Editing
We build cutting-edge genetic technologies with 30 years of research in diagnostics and 20 years of development in specialized gene editing.
Game-Changing Innovations in Genetics & Behavioral Health
We became the first company in US history to receive a full patent on a genetic test. Also patented in over 20 countries globally
We discovered the first genes linked to addiction and behavioral disease, developed over 30 years of research, and pioneered the field of Behavioral Genetics
We created a new field of science now taught in medical schools called Reward Deficiency Syndrome (RDS), which is the driver for behavioral disease
We have a large portfolio of biotech and genetic patents that will continue to break new ground for years in diagnostics and gene editing
We are building one of the largest behavioral disease and genetics databases in the world to advance research and the future of genetic technology
We created the first truly direct-to-consumer genetics platform and app, MyGenx, to provide actionable genetic data in a relatable format to help people transform their lives
We are the first company to develop neuronutrients that are personalized to a person’s genetics for dopamine regulation, backed by 37 published clinical studies
We are pioneering specialized gene editing technologies to resolve inherited behavioral disease. We have over 20 years of R&D coding the software of life
We created GARS (Genetic Addiction Risk Severity), the first genetic test that identifies risk for addiction and genetic mutations that lead to potential for behavioral disease
We created GORS (Genetic Obesity Risk Severity), the first genetic test that determines an individual’s epigenetic propensity and health risk for obesity
We became the first company in US history to receive a full patent on a genetic test. Also patented in over 20 countries globally
We discovered the first genes linked to addiction and behavioral disease, developed over 30 years of research, and pioneered the field of Behavioral Genetics
We created a new field of science now taught in medical schools called Reward Deficiency Syndrome (RDS), which is the driver for behavioral disease
We have a large portfolio of biotech and genetic patents that will continue to break new ground for years in diagnostics and gene editing
We are building one of the largest behavioral disease and genetics databases in the world to advance research and the future of genetic technology
We created the first truly direct-to-consumer genetics platform and app, MyGenx, to provide actionable genetic data in a relatable format to help people transform their lives
We are the first company to develop neuronutrients that are personalized to a person’s genetics for dopamine regulation, backed by 37 published clinical studies
We are pioneering specialized gene editing technologies to resolve inherited behavioral disease. We have over 20 years of R&D coding the software of life
We created GARS (Genetic Adddiction Risk Severity), the first genetic test that identifies risk for addiction and genetic mutations that lead to potential for behavioral disease
We created GORS (Genetic Obesity Risk Severity), the first genetic test that determines an individual’s epigenetic propensity and health risk for obesity
Our Companies
Our Companies
The inGeneUs family of companies are at the forefront of genetic technology, working seamlessly toward the goal of Epigenetic Resolution of diseases caused by genetic mutation.
By collaborating and understanding the entire process, from research to delivery, our teams have been able to introduce change and innovation where none has existed for decades. In unison, we excel at helping clinicians and clients save and transform lives.
Our teams have been able to introduce change and innovation
The inGeneUs family of companies are at the forefront of genetic technology, working seamlessly toward the goal of Epigenetic Resolution of diseases caused by genetic mutation.
By collaborating and understanding the entire process, from research to delivery, our teams have been able to introduce change and innovation where none has existed for decades. In unison, we excel at helping clinicians and clients save and transform lives.
Our teams have been able to introduce change and innovation
In The News
In The News
Organizations
We have partnered and collaborated with some of the most respected academic and research institutions nationwide and internationally
Organizations
We have partnered and collaborated with some of the most respected academic and research institutions nationwide and internationally
Recent Accomplishments
Recent Accomplishments
Full patent on genetic test for identifying risk for addiction and behavioral disease. Patent # 10,072,289 B2. Also patented in over 20 countries globally
“Top 100 Healthcare Visionaries” award from International Forum on Advancements in Healthcare (IFAH)
2015 – 2019 CAP Center of Excellence award
We are one of less than fifty nationally designated genetics labs by Centers for Disease Control and Prevention (CDC)
Funded by the NIH for a new standard of care with GARS Grant # 1R41MD012318-01
GARS accepted for FDA Breakthrough Technology Submission and pending final FDA approval
Awarded multiple VA contracts and received highest quality rating from VA for our molecular testing
2018 Top 10 Innovative Genetic Testing Company (Pharma Tech)
Featured in Sober World magazine, Campus Recovery magazine, Spectrum News, CBS News, and dozens of domestic and international conferences
Collaborative genetic partner with the U.S. National Human Genome Center in Washington, DC
